ANG Lifesciences India Ltd
ANG Lifesciences India Ltd (ANG) last traded at ₹26.8, a market capitalisation of ₹35 crore. Over the past 52 weeks the stock has ranged between ₹17.6 and ₹49.7. ANG Lifesciences India Ltd last reported results for the quarter ended Jun 2026, with sales of ₹15.3 crore and net profit of ₹-4.24 crore. Figures are as of 25 Aug 2026 and are not real time.
ANG Lifesciences India Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
ANG Lifesciences India Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹15.3 cr, down 37.8% from ₹24.6 cr a year earlier. Net profit was ₹-4.24 cr, down 110.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 32.88 | 24.73 | 16.82 | 24.6 | 26.05 | 18.73 | 23.5 | 15.3 |
| Expenses | 30.6 | 26.88 | 17.52 | 23.95 | 25.97 | 21.41 | 20.82 | 17.25 |
| Operating profit | 2.28 | -2.15 | -0.7 | 0.65 | 0.08 | -2.68 | 2.68 | -1.95 |
| OPM % | 6.93% | -8.69% | -4.16% | 2.64% | 0.31% | -14.31% | 11.40% | -12.75% |
| Other income | 0.35 | -0.27 | 0.65 | 0.09 | 0.12 | 0.16 | 0.17 | 0.11 |
| Interest | 2.18 | 2 | 2.42 | 1.94 | 1.89 | 1.93 | 2.18 | 2.24 |
| Depreciation | 1.74 | 1.96 | 1.42 | 1.53 | 1.52 | 1.51 | 1.77 | 1.5 |
| Profit before tax | -1.29 | -6.38 | -3.89 | -2.73 | -3.21 | -5.96 | -1.1 | -5.58 |
| Tax % | 62.02% | -18.65% | -47.04% | -26.74% | -8.41% | -20.30% | 25.45% | -24.01% |
| Net profit | -2.09 | -5.19 | -2.06 | -2.01 | -2.95 | -4.75 | -1.38 | -4.24 |
| EPS (₹) | -1.60 | -3.97 | -1.58 | -1.54 | -2.26 | -3.64 | -1.06 | -3.25 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
ANG Lifesciences India Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 154 | 354 | 220 | 145 | 93 | 93 | 84 |
| Operating profit | 14 | 68 | 15 | 10 | -1 | 1 | -2 |
| OPM % | 9% | 19% | 7% | 7% | -1.6% | 0.8% | -2.2% |
| Net profit | 7 | 40 | -0 | -10 | -12 | -11 | -13 |
| EPS (₹) | 5.26 | 31.02 | -0.20 | -7.77 | -9.50 | -8.49 | -10.21 |
TTM is the trailing twelve months to the most recent quarter.
ANG Lifesciences India Ltd growth and returns
- 10 Years
- %
- 5 Years
- -10%
- 3 Years
- -25%
- TTM
- -16%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -17%
- 10 Years
- %
- 5 Years
- -33%
- 3 Years
- -30%
- 1 Year
- -9%
- 10 Years
- %
- 5 Years
- 2%
- 3 Years
- -15%
- Last Year
- -19%
ANG Lifesciences India Ltd shareholding pattern
Promoters held 70.60% at Mar 2026, broadly unchanged since Mar 2025.
| % held | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% |
| Public | 29.39% | 29.39% | 29.39% | 29.39% | 29.40% | 29.40% | 29.41% | 29.40% |
| No. of shareholders | 6,631 | 6,468 | 6,517 | 6,508 | 6,400 | 6,273 | 6,084 | 5,952 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
ANG Lifesciences India Ltd corporate filings
- Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 2015Board Meetinghigh impact
Cruxal's analysis: ANG Lifesciences India Limited reported a weak financial performance for the quarter…
Read the full analysis - ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Standalone and Consolidated ....Board Meetinglow impact
Cruxal's analysis: ANG Lifesciences India Limited has issued a formal intimation regarding a Board of…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track ANG Lifesciences India Ltd
Cruxal reads every ANG Lifesciences India Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.